Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Drugs as Possible Triggers of Takotsubo Cardiomyopathy- Update 2022: Systematic Review

Author(s): Valentina Lopera, Jaime Andrés Pereañez and Pedro Jose Amariles*

Volume 21, Issue 5, 2023

Published on: 22 June, 2023

Page: [304 - 315] Pages: 12

DOI: 10.2174/1570161121666230517121037

Price: $65

Abstract

Background: A list of drugs that can induce takotsubo cardiomyopathy (TCM) was published in 2011 and 2016. The aim of the present review was to update this list.

Methods: Similar to the 2011 and 2016 reviews, from April 2015 to May 2022 case reports of druginduced TCM were identified by a comprehensive search in Medline/PubMed database. The search terms were: takotsubo cardiomyopathy, tako-tsubo cardiomyopathy, stress cardiomyopathy, transientleft- ventricular ballooning syndrome, apical ballooning syndrome, ampulla cardiomyopathy OR broken heart syndrome; together with “iatrogenic”, “induced by” OR “drug-induced”. Registers published in English or Spanish, in humans, and with full texts were retrieved. Articles that recognized any drug associated with the development of TCM were selected.

Results: Overall, 184 manuscripts were identified by the search. A total of 39 articles were included after an exhaustive revision. Eighteen drugs as possible triggers of TCM were identified in the current update. Of them, 3 (16.7%) have been previously identified, and 15 (83.3%) are different from the previous reports. Thus, the list of drugs as possible triggers of TCM updated in 2022 includes 72 drugs.

Conclusion: There are new case reports that link drugs with the development of TCM. The current list is principally made up of drugs that generate sympathetic overstimulation. However, some of the listed drugs do not have a clear link with sympathetic activation.

« Previous Next »
Graphical Abstract

[1]
Singh T, Khan H, Gamble DT, Scally C, Newby DE, Dawson D. Takotsubo syndrome: Pathophysiology, emerging concepts, and clinical implications. Circulation 2022; 145(13): 1002-19.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.121.055854] [PMID: 35344411]
[2]
Dote K, Sato H, Tateishi H, Uchida T, Ishihara M. Myocardial stunning due to simultaneous multivessel coronary spasms: A review of 5 cases. J Cardiol 1991; 21(2): 203-14.
[PMID: 1841907]
[3]
Medina de Chazal H, Del Buono MG, Keyser-Marcus L, et al. Stress cardiomyopathy diagnosis and treatment. J Am Coll Cardiol 2018; 72(16): 1955-71.
[http://dx.doi.org/10.1016/j.jacc.2018.07.072] [PMID: 30309474]
[4]
Bybee KA, Prasad A. Stress-related cardiomyopathy syndromes. Circulation 2008; 118(4): 397-409.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.677625] [PMID: 18645066]
[5]
Kurowski V, Kaiser A, von Hof K, et al. Apical and midventricular transient left ventricular dysfunction syndrome (tako-tsubo cardiomyo-pathy): Frequency, mechanisms, and prognosis. Chest 2007; 132(3): 809-16.
[http://dx.doi.org/10.1378/chest.07-0608] [PMID: 17573507]
[6]
Madhavan M, Prasad A. Proposed mayo clinic criteria for the diagnosis of tako-tsubo cardiomyopathy and long-term prognosis. Herz 2010; 35(4): 240-4.
[http://dx.doi.org/10.1007/s00059-010-3339-x] [PMID: 20582391]
[7]
Templin C, Ghadri JR, Diekmann J, et al. Clinical features and outcomes of takotsubo (Stress) cardiomyopathy. N Engl J Med 2015; 373(10): 929-38.
[http://dx.doi.org/10.1056/NEJMoa1406761] [PMID: 26332547]
[8]
Kanaoka K, Okayama S, Terasaki S, et al. Role of climatic factors in the incidence of Takotsubo syndrome: A nationwide study from 2012 to 2016. ESC Heart Fail 2020; 7(5): 2629-36.
[http://dx.doi.org/10.1002/ehf2.12843] [PMID: 32715646]
[9]
Tsuchihashi K, Ueshima K, Uchida T, et al. Transient left ventricular apical ballooning without coronary artery stenosis: A novel heart syndrome mimicking acute myocardial infarction. J Am Coll Cardiol 2001; 38(1): 11-8.
[http://dx.doi.org/10.1016/S0735-1097(01)01316-X] [PMID: 11451258]
[10]
Deshmukh A, Kumar G, Pant S, Rihal C, Murugiah K, Mehta JL. Prevalence of takotsubo cardiomyopathy in the United States. Am Heart J 2012; 164(1): 66-71.e1.
[http://dx.doi.org/10.1016/j.ahj.2012.03.020] [PMID: 22795284]
[11]
Williams R, Arri S, Prasad A. Current concepts in the pathogenesis of takotsubo syndrome. Heart Fail Clin 2016; 12(4): 473-84.
[http://dx.doi.org/10.1016/j.hfc.2016.06.002] [PMID: 27638018]
[12]
Litvinov IV, Kotowycz MA, Wassmann S. Iatrogenic epinephrine-induced reverse Takotsubo cardiomyopathy: Direct evidence supporting the role of catecholamines in the pathophysiology of the “broken heart syndrome”. Clin Res Cardiol 2009; 98(7): 457-62.
[http://dx.doi.org/10.1007/s00392-009-0028-y] [PMID: 19513776]
[13]
Abraham J, Mudd JO, Kapur N, Klein K, Champion HC, Wittstein IS. Stress cardiomyopathy after intravenous administration of catecholamines and beta-receptor agonists. J Am Coll Cardiol 2009; 53(15): 1320-5.
[http://dx.doi.org/10.1016/j.jacc.2009.02.020] [PMID: 19358948]
[14]
Amariles P. A comprehensive literature search: Drugs as possible triggers of Takotsubo cardiomyopathy. Curr Clin Pharmacol 2011; 6(1): 1-11.
[http://dx.doi.org/10.2174/157488411794941340] [PMID: 21235467]
[15]
Amariles P, Cifuentes L. Drugs as possible triggers of takotsubo cardiomyopathy: A comprehensive literature search – update 2015. Curr Clin Pharmacol 2016; 11(2): 95-109.
[http://dx.doi.org/10.2174/1574884711666160405105841] [PMID: 27049039]
[16]
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021; 372(71): n71.
[http://dx.doi.org/10.1136/bmj.n71] [PMID: 33782057]
[17]
Yamamoto W, Nishihara T, Nakanishi K, et al. Takotsubo cardiomyopathy induced by very low-dose epinephrine contained in local anesthetics: A case report. Am J Case Rep 2021; 22: e932028.
[http://dx.doi.org/10.12659/AJCR.932028] [PMID: 34174047]
[18]
Maes S, Dhooghe NSJJ, Schotte H, Cattoir S, Jacobs TF, Van Landuyt K. Takotsubo cardiomyopathy induced by epinephrine infiltration for liposuction: broken heart syndrome. Aesthet Surg J 2019; 39(10): NP431-6.
[http://dx.doi.org/10.1093/asj/sjz201] [PMID: 31504179]
[19]
Rader T, Bailey K, Flora AS. Iatrogenic takotsubo cardiomyopathy. Am J Ther 2018; 25(6): e695-8.
[http://dx.doi.org/10.1097/MJT.0000000000000707] [PMID: 30398995]
[20]
Keshtkar F, Dale OT, Bennett WO, Hall CE. Management of airway obstruction with nebulised adrenaline resulting in takotsubo cardiomyopathy: Case report. J Laryngol Otol 2016; 130(9): 883-6.
[http://dx.doi.org/10.1017/S0022215116008288] [PMID: 27377118]
[21]
Gicquel-Schlemmer B, Beller JP, Mchalwat A, Gicquel P. Fatal Takotsubo cardiomyopathy due to epinephrine in shoulder arthroscopy. Orthop Traumatol Surg Res 2015; 101(8): 981-2.
[http://dx.doi.org/10.1016/j.otsr.2015.09.026] [PMID: 26548514]
[22]
Ghanim D, Adler Z, Qarawani D, Kusniec F, Amir O, Carasso S. Takotsubo cardiomyopathy caused by epinephrine-treated bee sting anaphylaxis: A case report. J Med Case Reports 2015; 9(1): 247.
[http://dx.doi.org/10.1186/s13256-015-0722-5] [PMID: 26518383]
[23]
Patankar GR, Donsky MS, Schussler JM. Delayed takotsubo cardiomyopathy caused by excessive exogenous epinephrine administration after the treatment of angioedema. Proc Bayl Univ Med Cent 2012; 25(3): 229-30.
[http://dx.doi.org/10.1080/08998280.2012.11928833] [PMID: 22754120]
[24]
Scheiba N, Viedt-Suelmann C, Schäkel K. Tako-tsubo cardiomyopathy after a hymenoptera sting and treatment with catecholamines. Acta Derm Venereol 2011; 91(5): 593-4.
[http://dx.doi.org/10.2340/00015555-1119] [PMID: 21547339]
[25]
Nazir S, Melnick S, Lohani S, Lloyd B. Rare case of stress cardiomyopathy due to intramuscular epinephrine administration. BMJ Case Rep 2016; 2016: bcr2016215691.
[http://dx.doi.org/10.1136/bcr-2016-215691] [PMID: 27268785]
[26]
Imnadze G, Metreveli L, Franz N, Thale J. Case of Takotsubo cardiomyopathy after tooth extraction – Unusual trigger of a rare syndrome. J Cardiol Cases 2014; 10(4): 129-31.
[http://dx.doi.org/10.1016/j.jccase.2014.06.007] [PMID: 30534223]
[27]
Koo MS, Lee JW, Kim DH, Sir JJ, Kim JM. Inverted stress cardiomyopathy during monitored anesthesia care for endoscopic sinus surgery. Korean J Anesthesiol 2013; 65(S6): S79-81.
[http://dx.doi.org/10.4097/kjae.2013.65.6S.S79] [PMID: 24478883]
[28]
Murthy A, Henien S, Mcpherson CA, Logue MA. Epinephrine use results in ‘stress’ cardiomyopathy. J Cardiol Cases 2015; 11(3): 85-7.
[http://dx.doi.org/10.1016/j.jccase.2014.11.001] [PMID: 30546537]
[29]
Ouerghi K, Boukhris M, Grall S, Desprets L, Quercy M. Reverse iatrogenic Takotsubo syndrome after accidental bolus of norepinephrine in the setting of sepsis. Kardiol Pol 2016; 74(8): 799.
[http://dx.doi.org/10.5603/KP.2016.0117] [PMID: 27553351]
[30]
Chen YH, Lai HC, Lee WL, Liu TJ. Iatrogenic takotsubo cardiomyopathy following overdose norepinephrine administration during percutaneous coronary intervention. Int Heart J 2020; 61(6): 1298-302.
[http://dx.doi.org/10.1536/ihj.20-118] [PMID: 33116021]
[31]
Vailas MG, Vernadakis S, Kakavia K, et al. A heartbreaking renal transplantation: Is norepinephrine the culprit to blame? Transplant Proc 2016; 48(9): 3088-91.
[http://dx.doi.org/10.1016/j.transproceed.2016.05.014] [PMID: 27932153]
[32]
Sherif K, Sehli S, Jenkins LA. Takotsubo cardiomyopathy after administration of norepinephrine. Proc Bayl Univ Med Cent 2016; 29(2): 166-7.
[http://dx.doi.org/10.1080/08998280.2016.11929402] [PMID: 27034556]
[33]
Vieira A, Batista B, de Abreu TT. Iatrogenic takotsubo cardiomyopathy secondary to norepinephrine by continuous infusion for shock. Eur J Case Rep Intern Med 2018; 5: 1.
[http://dx.doi.org/10.12890/2018_000894] [PMID: 30756050]
[34]
Subramaniam A, Cooke JC, Ernest D. “Inverted” tako-tsubo cardiomyopathy due to exogenous catecholamines. Crit Care Resusc 2010; 12(2): 104-8.
[PMID: 20513218]
[35]
Lee A, Nguyen P. Takotsubo cardiomyopathy due to systemic absorption of intraocular phenylephrine. Heart Lung Circ 2016; 25(12): e159-61.
[http://dx.doi.org/10.1016/j.hlc.2016.06.1204] [PMID: 27475260]
[36]
Parsa SA, Khaheshi I, Memaryan M, Naderian M. Takotsubo cardiomyopathy following recurrent doses of albuterol due to asthma attack: A very rare case report. Future Cardiol 2016; 12(6): 609-12.
[http://dx.doi.org/10.2217/fca-2016-0040] [PMID: 27759421]
[37]
Nakao M, Kawaai S, Nakamura D, Tsunoda A. Takotsubo cardiomyopathy during electrophysiological study with isoproterenol. Int J Cardiol 2016; 223: 521-3.
[http://dx.doi.org/10.1016/j.ijcard.2016.08.170] [PMID: 27552570]
[38]
Ozpelit E, Ozpelit ME, Akdeniz B, Göldeli Ö. Ergotamine-induced takotsubo cardiomyopathy. Am J Ther 2016; 23(2): e597-600.
[http://dx.doi.org/10.1097/MJT.0000000000000030] [PMID: 25099482]
[39]
Baldacci F, Vergallo A, Del Dotto P, et al. Occurrence of Takotsubo syndrome in a patient with Parkinson’s disease after entacapone add-on. Parkinsonism Relat Disord 2014; 20(11): 1313-4.
[http://dx.doi.org/10.1016/j.parkreldis.2014.09.009] [PMID: 25258328]
[40]
Melão F, Nunes JP, Vasconcelos M, et al. Stress-induced cardiomyopathy associated with ipratropium bromide therapy in a patient with chronic obstructive pulmonary disease. Rev Port Cardiol 2014; 33(3): 175.e1-4.
[http://dx.doi.org/10.1016/j.repc.2013.10.012] [PMID: 24680554]
[41]
Nakagawa N, Fukawa N, Tsuji K, Nakano N, Kato A. Takotsubo cardiomyopathy induced by dopamine infusion after carotid artery stenting. Int J Cardiol 2016; 205: 62-4.
[http://dx.doi.org/10.1016/j.ijcard.2015.12.023] [PMID: 26716585]
[42]
Jamshidi N, Clark D, Murnion B. Recurrent takotsubo cardiomyopathy associated with opioid withdrawal during buprenorphine induction. Cardiovasc Toxicol 2021; 21(5): 349-53.
[http://dx.doi.org/10.1007/s12012-020-09624-z] [PMID: 33481183]
[43]
Surmaitis RM, Khalid MM, Vearrier D, Greenberg MI. Takotsubo cardiomyopathy associated with buprenorphine precipitated withdrawal. Clin Toxicol 2018; 56(9): 863-4.
[http://dx.doi.org/10.1080/15563650.2018.1437921] [PMID: 29433361]
[44]
Ovadia D, Esquenazi Y, Bucay M, Bachier CR. Association between takotsubo cardiomyopathy and axitinib: Case report and review of the literature. J Clin Oncol 2015; 33(1): e1-3.
[http://dx.doi.org/10.1200/JCO.2013.48.7280] [PMID: 24567431]
[45]
Franco T, Khan A, Joshi V, Thomas B. Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer. Ther Clin Risk Manag 2008; 4(6): 1367-70.
[http://dx.doi.org/10.2147/TCRM.S3960] [PMID: 19337443]
[46]
Rojas-Marte G, John J, Sadiq A, Moskovits N, Saunders P, Shani J. Medication-induced Takotsubo Cardiomyopathy presenting with cardiogenic shock—utility of extracorporeal membrane oxygenation (ECMO): Case report and review of the literature. Cardiovasc Revasc Med 2015; 16(1): 47-51.
[http://dx.doi.org/10.1016/j.carrev.2014.07.004] [PMID: 25172356]
[47]
Damodaran S, Mrozek E, Liebner D, Kendra K. Focal takotsubo cardiomyopathy with high-dose interleukin-2 therapy for malignant melanoma. J Natl Compr Canc Netw 2014; 12(12): 1666-70.
[http://dx.doi.org/10.6004/jnccn.2014.0168] [PMID: 25505207]
[48]
Candilio L, Moon T, Sado D, Dworakowski R. Iatrogenic corticosteroids induced Takotsubo cardiomyopathy. Cardiovasc Revasc Med 2018; 19(4): 471-3.
[http://dx.doi.org/10.1016/j.carrev.2017.09.013] [PMID: 29122525]
[49]
Auboire L, Alexandre J, Boccadamo V, Labbé C. Tako-tsubo syndrome induced by a polidecanol injection: A case report. Int J Cardiol 2016; 223: 418-9.
[http://dx.doi.org/10.1016/j.ijcard.2016.08.196] [PMID: 27552562]
[50]
Potter BJ, Gobeil F, Oiknine A, Laramée P. The first case of takotsubo cardiomyopathy associated with sodium tetradecyl sulphate sclero-therapy. Can J Cardiol 2010; 26(4): e146-8.
[http://dx.doi.org/10.1016/S0828-282X(10)70373-1] [PMID: 20386776]
[51]
Kamada T, Hayashi M, Yokoi H, et al. Takotsubo cardiomyopathy with involvement of delayed-onset rhabdomyolysis and acute kidney injury after rosuvastatin treatment. Intern Med 2015; 54(1): 31-5.
[http://dx.doi.org/10.2169/internalmedicine.54.3239] [PMID: 25742890]
[52]
Hilal-Dandan R, Brunton LL. Goodman & Gilman Manual of pharmacology and therapeutics. (2nd ed.), Madrid, Spain: McGraw-Hill Interamerican Publishers 2015.
[53]
Brunton LL, Chabner BA, Knollmann BC. Goodman & Gilman: The Pharmacological Basis of Therapeutics. (13 ed.), New York, USA: McGraw Hill 2019.
[54]
Kido K, Guglin M. Drug-induced takotsubo cardiomyopathy. J Cardiovasc Pharmacol Ther 2017; 22(6): 552-63.
[http://dx.doi.org/10.1177/1074248417708618] [PMID: 28490198]
[55]
Boyd B, Solh T. Takotsubo cardiomyopathy. JAAPA 2020; 33(3): 24-9.
[http://dx.doi.org/10.1097/01.JAA.0000654368.35241.fc] [PMID: 32039951]
[56]
Tfelt-Hansen P, Saxena PR, Dahlöf C, et al. Ergotamine in the acute treatment of migraine: A review and European consensus. Brain 2000; 123(1): 9-18.
[http://dx.doi.org/10.1093/brain/123.1.9] [PMID: 10611116]
[57]
Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. (13 ed.), New York: McGraw-Hill 2017.
[58]
Monti M, Cortesi P, Vespignani R, et al. Takotsubo Syndrome (TTS) in onco-hematologic patients: Retrospective analysis and focus on the correlation or not with anticancer drugs. Case reports and review of the literature. Front Oncol 2022; 12: 875391.
[http://dx.doi.org/10.3389/fonc.2022.875391] [PMID: 35692777]
[59]
Budnik M, Kucharz J, Wiechno P, et al. Chemotherapy-induced takotsubo syndrome. Adv Exp Med Biol 2018; 1114: 19-29.
[http://dx.doi.org/10.1007/5584_2018_222] [PMID: 29884920]
[60]
Li Y, Tian W, Yue D, et al. Bevacizumab-induced mitochondrial dysfunction, endoplasmic reticulum stress, and ERK inactivation contribute to cardiotoxicity. Oxid Med Cell Longev 2021; 2021: 1-11.
[http://dx.doi.org/10.1155/2021/5548130] [PMID: 33859777]
[61]
Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J. Vascular and metabolic implications of novel targeted cancer therapies. J Am Coll Cardiol 2015; 66(10): 1160-78.
[http://dx.doi.org/10.1016/j.jacc.2015.07.025] [PMID: 26337996]
[62]
Pun SC, Neilan TG. Cardiovascular side effects of small molecule therapies for cancer: Table 1. Eur Heart J 2016; 37(36): 2742-5.
[http://dx.doi.org/10.1093/eurheartj/ehw361] [PMID: 27694541]
[63]
Porzionato A, Macchi V, De Caro R, Di Giulio C. Inflammatory and immunomodulatory mechanisms in the carotid body. Respir Physiol Neurobiol 2013; 187(1): 31-40.
[http://dx.doi.org/10.1016/j.resp.2013.02.017] [PMID: 23485800]
[64]
Smith RS, Warren DJ. Effects of high-dose intravenous methylprednisolone on circulation in humans. Transplantation 1983; 35(4): 349-51.
[http://dx.doi.org/10.1097/00007890-198304000-00017] [PMID: 6836710]
[65]
Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 2000; 16(4): 505-11.
[PMID: 10787466]
[66]
Golicnik A, Vrtacnik Bokal E, Gorjup V. Cardiac arrest and inverted takotsubo cardiomyopathy following intramyometrial vasopressin injec-tion during myomectomy. Eur J Case Rep Intern Med 2021; 8(5): 9.
[http://dx.doi.org/10.12890/2021_002504] [PMID: 34123941]
[67]
Morimoto T, Katanasaka Y, Sunagawa Y, et al. Effects of statins on left ventricular diastolic function in patients with dyslipidemia and diastolic dysfunction (Stat-LVDF Study). Biol Pharm Bull 2015; 38(9): 1404-9.
[http://dx.doi.org/10.1248/bpb.b15-00126] [PMID: 26328497]
[68]
Talini E, Di Bello V, Bianchi C, et al. Early impairment of left ventricular function in hypercholesterolemia and its reversibility after short term treatment with rosuvastatin. Atherosclerosis 2008; 197(1): 346-54.
[http://dx.doi.org/10.1016/j.atherosclerosis.2007.05.024] [PMID: 17631295]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy